Jing Wang, Shaojie Ye, Huimei Guo, Songying Zhao, Jia Liu, JiangBo Zhang, Jianmei Xu, Xi Su, Luoming Hua, Hua Xue
{"title":"16例原发性轻链型心脏淀粉样变性包括IIIb期患者的单中心临床疗效分析。","authors":"Jing Wang, Shaojie Ye, Huimei Guo, Songying Zhao, Jia Liu, JiangBo Zhang, Jianmei Xu, Xi Su, Luoming Hua, Hua Xue","doi":"10.1007/s10238-025-01616-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical efficacy of daratumumab versus bortezomib in patients with systemic light chain amyloidosis (pAL) with cardiac involvement, particularly those at stage IIIb.</p><p><strong>Methods: </strong>Retrospective analysis of 16 AL patients with cardiac involvement, two groups of patients received treatment primarily with bortezomib and daratumumab, respectively. The hematologic remission rate, cardiac response rate, survival and adverse reactions of the two groups were analyzed.</p><p><strong>Results: </strong>Among the 16 patients, 4 were classified as Mayo 2004 stage IIIa and 6 as stage IIIb. The hematological response rate and cardiac organ response rate were higher in the daratumumab group compared to the bortezomib group (71% vs. 33%; 57% vs. 11%). With a median follow-up of 12 months, the median progression-free survival (PFS) and overall survival (OS) were superior in the daratumumab group (not reached vs. 6 months, P = 0.022; 27.8 months vs. 21.7 months, P = 0.232).Specifically, among the 6 stage IIIb patients, the daratumumab group demonstrated higher hematological and cardiac response rates (66% vs. 0%; 66% vs. 0%).</p><p><strong>Conclusions: </strong>For patients with AL amyloidosis and cardiac involvement,including those at stage IIIb, daratumumab-based regimens offer benefits in terms of hematological remission, cardiac response, and progression-free survival, with comparable tolerability to bortezomib.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"85"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911256/pdf/","citationCount":"0","resultStr":"{\"title\":\"Single-center clinical efficacy analysis of 16 cases of primary light chain cardiac amyloidosis including stage IIIb patients.\",\"authors\":\"Jing Wang, Shaojie Ye, Huimei Guo, Songying Zhao, Jia Liu, JiangBo Zhang, Jianmei Xu, Xi Su, Luoming Hua, Hua Xue\",\"doi\":\"10.1007/s10238-025-01616-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To investigate the clinical efficacy of daratumumab versus bortezomib in patients with systemic light chain amyloidosis (pAL) with cardiac involvement, particularly those at stage IIIb.</p><p><strong>Methods: </strong>Retrospective analysis of 16 AL patients with cardiac involvement, two groups of patients received treatment primarily with bortezomib and daratumumab, respectively. The hematologic remission rate, cardiac response rate, survival and adverse reactions of the two groups were analyzed.</p><p><strong>Results: </strong>Among the 16 patients, 4 were classified as Mayo 2004 stage IIIa and 6 as stage IIIb. The hematological response rate and cardiac organ response rate were higher in the daratumumab group compared to the bortezomib group (71% vs. 33%; 57% vs. 11%). With a median follow-up of 12 months, the median progression-free survival (PFS) and overall survival (OS) were superior in the daratumumab group (not reached vs. 6 months, P = 0.022; 27.8 months vs. 21.7 months, P = 0.232).Specifically, among the 6 stage IIIb patients, the daratumumab group demonstrated higher hematological and cardiac response rates (66% vs. 0%; 66% vs. 0%).</p><p><strong>Conclusions: </strong>For patients with AL amyloidosis and cardiac involvement,including those at stage IIIb, daratumumab-based regimens offer benefits in terms of hematological remission, cardiac response, and progression-free survival, with comparable tolerability to bortezomib.</p>\",\"PeriodicalId\":10337,\"journal\":{\"name\":\"Clinical and Experimental Medicine\",\"volume\":\"25 1\",\"pages\":\"85\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-03-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911256/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10238-025-01616-z\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-025-01616-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
目的:探讨达拉单抗与硼替佐米在系统性轻链淀粉样变性(pAL)伴心脏受累(特别是IIIb期)患者中的临床疗效。方法:回顾性分析16例AL累及心脏患者,两组患者分别以硼替佐米和达拉单抗为主治疗。分析两组患者血液学缓解率、心脏反应率、生存期及不良反应。结果:16例患者中,4例为Mayo 2004期IIIa期,6例为IIIb期。达拉单抗组的血液学反应率和心脏器官反应率高于硼替佐米组(71% vs 33%;57%对11%)。中位随访时间为12个月,达拉单抗组的中位无进展生存期(PFS)和总生存期(OS)均优于达拉单抗组(未达到vs. 6个月,P = 0.022;27.8个月vs. 21.7个月,P = 0.232)。具体来说,在6例IIIb期患者中,daratumumab组显示出更高的血液学和心脏反应率(66% vs 0%;66% vs. 0%)。结论:对于AL淀粉样变性和心脏受累的患者,包括IIIb期患者,基于daratumumab的方案在血液学缓解、心脏反应和无进展生存方面提供了益处,并且与硼替佐米具有相当的耐受性。
Single-center clinical efficacy analysis of 16 cases of primary light chain cardiac amyloidosis including stage IIIb patients.
Objective: To investigate the clinical efficacy of daratumumab versus bortezomib in patients with systemic light chain amyloidosis (pAL) with cardiac involvement, particularly those at stage IIIb.
Methods: Retrospective analysis of 16 AL patients with cardiac involvement, two groups of patients received treatment primarily with bortezomib and daratumumab, respectively. The hematologic remission rate, cardiac response rate, survival and adverse reactions of the two groups were analyzed.
Results: Among the 16 patients, 4 were classified as Mayo 2004 stage IIIa and 6 as stage IIIb. The hematological response rate and cardiac organ response rate were higher in the daratumumab group compared to the bortezomib group (71% vs. 33%; 57% vs. 11%). With a median follow-up of 12 months, the median progression-free survival (PFS) and overall survival (OS) were superior in the daratumumab group (not reached vs. 6 months, P = 0.022; 27.8 months vs. 21.7 months, P = 0.232).Specifically, among the 6 stage IIIb patients, the daratumumab group demonstrated higher hematological and cardiac response rates (66% vs. 0%; 66% vs. 0%).
Conclusions: For patients with AL amyloidosis and cardiac involvement,including those at stage IIIb, daratumumab-based regimens offer benefits in terms of hematological remission, cardiac response, and progression-free survival, with comparable tolerability to bortezomib.
期刊介绍:
Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.